Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
NCT03320434
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergic Conjunctivitis
Interventions
DRUG:
PRT-2761 0.5%
DRUG:
PRT-2761 1%
DRUG:
Patanol
DRUG:
Pred-forte
DRUG:
PRT-2761 0%
Sponsor
ORA, Inc.